Work

Supplementary Table S2 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

Year: 2023

Type: supplementary-materials

Abstract: Supplementary Table S2 from Bevacizumab Plus Irinotecan in Recurrent WHO Grade 3 Malignant Gliomas

DOI: 10.1158/1078-0432.22439442.v1

Authors: Annick Desjardins, David A. Reardon, James E. Herndon, Jennifer Marcello, Jennifer A. Quinn, Jeremy N. Rich, Sith Sathornsumetee, Sridharan Gururangan, John Sampson, Leighann Bailey, Darell D. Bigner, Allan H. Friedman, Henry S. Friedman, James J. Vredenburgh

Language: English

Topic: Glioma Diagnosis and Treatment

Subfield: Genetics

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362430778

Cites:

Cited by:

Related to: 10